Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517679 | 1.00 | SLC6A3 (0.46) | SLC6A3CHRM4SLC6A2SLC6A4MAPT | |
| SCHEMBL5517668 | 1.00 | SLC6A3 (0.46) | SLC6A3CHRM4SLC6A2SLC6A4MAPT | |
| SCHEMBL5526201 | 0.90 | SLC6A3 (0.45) | SLC6A3CHRM4SLC6A2SLC6A4 | |
| SCHEMBL5526205 | 0.90 | SLC6A3 (0.45) | SLC6A3CHRM4SLC6A2SLC6A4 | |
| SCHEMBL5526202 | 0.90 | SLC6A3 (0.45) | SLC6A3CHRM4SLC6A2SLC6A4 | |
| SCHEMBL5521120 | 0.88 | CHRM4 (0.45) | CHRM4 | |
| SCHEMBL5521118 | 0.88 | CHRM4 (0.45) | CHRM4 | |
| SCHEMBL5521114 | 0.88 | CHRM4 (0.45) | CHRM4 | |
| SCHEMBL5521965 | 0.88 | CHRM4 (0.47) | CHRM4POLB | |
| SCHEMBL5521960 | 0.88 | CHRM4 (0.47) | CHRM4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | claimed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | SLC6A3 638/4885CHRM4 1218/4885SLC6A2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.